XBP1 and amelogenesis imperfecta type 1G: Meanwhile, 4-PBA and TUDCA application, usually acknowledged as ERS inhibitors and therapeutic agents to deal with ERS associated pathologies, effectively attenuated I/R-induced ERS activation (GRP78, XBP1 and CHOP expression were decreased and CHOP translocation from cytoplasm to nucleus was also attenuated), and more importantly, protected against renal tissues damage and cells apoptosis.